Drug Profile
Buprenorphine transdermal - Mundipharma
Alternative Names: BTDS; BuTrans; Butrans; Butrans Transdermal System CIII; Norspan; Norspan Tape; Restive; SovenorLatest Information Update: 09 Mar 2022
Price :
$50
*
At a glance
- Originator Mundipharma International
- Developer Grunenthal; Hisamitsu Pharmaceutical; Mundipharma International; Purdue Pharma
- Class Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
- Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor agonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pain
Most Recent Events
- 09 Mar 2022 Discontinued - Phase-III for Pain (In adolescents, In children) in USA (Transdermal)
- 08 Aug 2019 No development reported - Phase-III for Pain (In adolescents, In children) in USA (Transdermal)
- 03 Jun 2019 Mundipharma plans a phase III trial for Cancer pain in China (Transdermal) (NCT03967327)